WO2015018522A1 - Inhibiteur de bromodomaine bet présentant une synergie avec plusieurs agents anti-cancéreux dans des modèles cliniques de lymphome diffus de cellule b de grande taille (dlbcl) - Google Patents
Inhibiteur de bromodomaine bet présentant une synergie avec plusieurs agents anti-cancéreux dans des modèles cliniques de lymphome diffus de cellule b de grande taille (dlbcl) Download PDFInfo
- Publication number
- WO2015018522A1 WO2015018522A1 PCT/EP2014/002165 EP2014002165W WO2015018522A1 WO 2015018522 A1 WO2015018522 A1 WO 2015018522A1 EP 2014002165 W EP2014002165 W EP 2014002165W WO 2015018522 A1 WO2015018522 A1 WO 2015018522A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- carbon number
- solid dispersion
- thienotriazolodiazepine
- alkyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
L'invention concerne procédé de traitement de lymphome diffus de cellule B de grande taille chez un mammifère, comprenant l'étape consistant à administrer une quantité pharmaceutiquement acceptable d'une combinaison de médicaments anticancéreux à un patient, laquelle combinaison comprend un premier composé et un second composé; le premier composé est choisi dans le groupe comprenant un inhibiteur de mTOR, un inhibiteur de BTK, un inhibiteur de HDAC, un anticorps monoclonal anti CD20, un agent d'hypométhylation et un immunomodulateur; le second composant consiste en un composé de thiènotriazolodiazépine correpondant à la formule (1) où : R1 est alkyle comprenant 1-4 atomes de carbone; R2 est un atome d'hydrogène; un atome halogène; ou un alkyle comprenant 1-4 atomes de carbone éventuellement substitué par un atome halogène ou un groupe hydroxyle; R3 est un atome halogène; un phényle éventuellement substitué par un atome halogène, un alkyle comprenant 1-4 atomes de carbone, un alcoxy comprenant 1-4 atomes de carbone ou cyano; — NR5— (CH2)m— R6 où R5 est un atome d'hydrogène ou un alkyle comprenant 1-4 atomes de carbone, m est un nombre entier de 0-4, et R6 est phényle ou pyrdiyle éventuellement substitué par un atome halogène; ou -NR7— CO— (CH2)n— R8 où R7 est un atome d'hydrogène ou un alkyle comprenant 1-4 atomes de carbone, n est un nombre entier de 0-2 et R8 est un phényle ou pyrdiyle éventuellement substitué par un atome halogène, et R4 est — (CH2)a— CO— NH— R9 où a est un nombre entier de 1-4 et R9 est un alkyle comprenant 1-4 atomes de carbone; hydroxyalkyle comprenant 1-4 atomes de carbone; alcoxy comprenant 1-4 atomes de carbone; ou phényle ou pyrdiyle éventuellement substitué par un alkyle comprenant 1-4 atomes de carbone, alcoxy comprenant 1-4 atomes de carbone, amino ou un groupe hydroxyle ou — (CH2)b— COOR10 où b est un nombre entier de 1-4 et R10 est un alkyle comprenant 1-4 atomes de carbone; ou un sel pharmaceutiquement acceptable de celui-ci ou un hydrate ou solvate de celui-ci.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361862752P | 2013-08-06 | 2013-08-06 | |
US201361862772P | 2013-08-06 | 2013-08-06 | |
US61/862,752 | 2013-08-06 | ||
US61/862,772 | 2013-08-06 | ||
US201314619097A | 2013-11-27 | 2013-11-27 | |
US61//909,703 | 2013-11-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015018522A1 true WO2015018522A1 (fr) | 2015-02-12 |
Family
ID=52460696
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2014/002165 WO2015018522A1 (fr) | 2013-08-06 | 2014-08-06 | Inhibiteur de bromodomaine bet présentant une synergie avec plusieurs agents anti-cancéreux dans des modèles cliniques de lymphome diffus de cellule b de grande taille (dlbcl) |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2015018522A1 (fr) |
Cited By (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9290504B2 (en) | 2011-07-19 | 2016-03-22 | Merck Sharp & Dohme B.V. | 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as Btk inhibitors |
WO2016176335A1 (fr) | 2015-04-27 | 2016-11-03 | Concert Pharmaceuticals, Inc. | Otx-015 deutéré |
CN106146352A (zh) * | 2015-04-16 | 2016-11-23 | 上海医药工业研究院 | Idelalisib中间体及其制备方法 |
WO2017112703A1 (fr) * | 2015-12-24 | 2017-06-29 | Celgene Quanticel Research, Inc. | Thérapie d'association par inhibiteur de bromodomaine et de protéine extra-terminale |
US9718828B2 (en) | 2011-07-19 | 2017-08-01 | Merck Sharp & Dohme Corp. | BTK Inhibitors |
CN107033147A (zh) * | 2017-04-25 | 2017-08-11 | 东南大学 | 一种bet/hdac双靶点抑制剂及其制备方法和应用 |
WO2017059319A3 (fr) * | 2015-10-02 | 2017-10-12 | Dana-Farber Cancer Institute, Inc. | Polythérapie par inhibiteurs de bromodomaine et blocage de point de contrôle |
US9814721B2 (en) | 2010-06-03 | 2017-11-14 | Pharmacyclics Llc | Use of inhibitors of bruton'S tyrosine kinase (BTK) |
EP3137086A4 (fr) * | 2014-05-02 | 2017-12-27 | Oncoethix GmbH | Methode de traitement de lymphome non hodgkinien resistant, de medulloblastome et/ou de cancer bronchopulmonaire non a petites cellules alk+ a l'aide de composes de thienotriazolodiazepine |
WO2018013693A1 (fr) * | 2016-07-13 | 2018-01-18 | Celgene Corporation | Dispersions solides et co-cristaux comprenant des compositions de 3-(4-amino-1-oxo-1,3-dihydro-iso-indol-2-yl)-pipéridine-2,6-dione et procédés pour les utiliser |
US9885086B2 (en) | 2014-03-20 | 2018-02-06 | Pharmacyclics Llc | Phospholipase C gamma 2 and resistance associated mutations |
US9937171B2 (en) | 2014-04-11 | 2018-04-10 | Acerta Pharma B.V. | Methods of blocking the CXCR-4/SDF-1 signaling pathway with inhibitors of bruton's tyrosine kinase |
US9949971B2 (en) | 2014-06-17 | 2018-04-24 | Acerta Pharma B.V. | Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor and/or a JAK-2 inhibitor |
WO2018081475A1 (fr) * | 2016-10-27 | 2018-05-03 | Celgene Quanticel Research, Inc. | Polythérapie par inhibiteur de protéine à bromodomaine et domaine extra-terminal |
CN108033961A (zh) * | 2015-04-15 | 2018-05-15 | 上海方楠生物科技有限公司 | 一种艾德力布的无定型物及其制备方法 |
US10124009B2 (en) | 2014-10-27 | 2018-11-13 | Tensha Therapeutics, Inc. | Bromodomain inhibitors |
US10167291B2 (en) | 2015-07-02 | 2019-01-01 | Acerta Pharma B.V. | Pharmaceutical composition comprising a crystal form of (S)-4-(8-amino-3-(1-(but-2-ynoyl) pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide |
WO2019020606A1 (fr) * | 2017-07-26 | 2019-01-31 | F. Hoffmann-La Roche Ag | Polythérapie avec un inhibiteur bet, un inhibiteur bcl-2 et un anticorps anti-cd20 |
US10328080B2 (en) | 2013-12-05 | 2019-06-25 | Acerta Pharma, B.V. | Therapeutic combination of PI3K inhibitor and a BTK inhibitor |
US10407441B2 (en) | 2010-05-14 | 2019-09-10 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating neoplasia, inflammatory disease and other disorders |
US10676484B2 (en) | 2010-05-14 | 2020-06-09 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating leukemia |
US10906917B2 (en) | 2018-06-13 | 2021-02-02 | Dybly Ag | Preparation of condensed triazepine derivatives and their use as BET inhibitors |
US10925881B2 (en) | 2014-02-28 | 2021-02-23 | Tensha Therapeutics, Inc. | Treatment of conditions associated with hyperinsulinaemia |
US10954567B2 (en) | 2012-07-24 | 2021-03-23 | Pharmacyclics Llc | Mutations associated with resistance to inhibitors of Bruton's Tyrosine Kinase (BTK) |
US11084793B2 (en) | 2014-05-01 | 2021-08-10 | Celgene Quanticel Research, Inc. | Inhibitors of lysine specific demethylase-1 |
US11166951B2 (en) | 2014-08-11 | 2021-11-09 | Acerta Pharma B.V. | Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, a JAK-2 inhibitor, and/or a BCL-2 inhibitor |
US11446309B2 (en) | 2013-11-08 | 2022-09-20 | Dana-Farber Cancer Institute, Inc. | Combination therapy for cancer using bromodomain and extra-terminal (BET) protein inhibitors |
US11666580B2 (en) | 2015-08-10 | 2023-06-06 | Dana-Farber Cancer Institute, Inc. | Mechanism of resistance to bet bromodomain inhibitors |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1297836A1 (fr) * | 2000-06-16 | 2003-04-02 | Mitsubishi Pharma Corporation | Compositions permettant de reguler la plage et/ou la vitesse de liberation du ph |
EP2239264A1 (fr) * | 2007-12-28 | 2010-10-13 | Mitsubishi Tanabe Pharma Corporation | Agent antitumoral |
WO2011143669A2 (fr) * | 2010-05-14 | 2011-11-17 | Dana-Farber Cancer Institute, Inc | Compositions et méthodes de traitement des néoplasies, des maladies inflammatoires et d'autres affections |
WO2012075456A1 (fr) * | 2010-12-02 | 2012-06-07 | Constellation Pharmaceuticals | Inhibiteurs de bromodomaines et leurs utilisations |
WO2014001356A1 (fr) * | 2012-06-25 | 2014-01-03 | Oncoethix Sa | Méthode de traitement d'un lymphome à l'aide de composés thiénotriazolodiazépine |
WO2014068402A2 (fr) * | 2012-09-28 | 2014-05-08 | Oncoethix Sa | Formulation pharmaceutique contenant des composés thienotriazolodiazepine |
-
2014
- 2014-08-06 WO PCT/EP2014/002165 patent/WO2015018522A1/fr active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1297836A1 (fr) * | 2000-06-16 | 2003-04-02 | Mitsubishi Pharma Corporation | Compositions permettant de reguler la plage et/ou la vitesse de liberation du ph |
EP2239264A1 (fr) * | 2007-12-28 | 2010-10-13 | Mitsubishi Tanabe Pharma Corporation | Agent antitumoral |
WO2011143669A2 (fr) * | 2010-05-14 | 2011-11-17 | Dana-Farber Cancer Institute, Inc | Compositions et méthodes de traitement des néoplasies, des maladies inflammatoires et d'autres affections |
WO2012075456A1 (fr) * | 2010-12-02 | 2012-06-07 | Constellation Pharmaceuticals | Inhibiteurs de bromodomaines et leurs utilisations |
WO2014001356A1 (fr) * | 2012-06-25 | 2014-01-03 | Oncoethix Sa | Méthode de traitement d'un lymphome à l'aide de composés thiénotriazolodiazépine |
WO2014068402A2 (fr) * | 2012-09-28 | 2014-05-08 | Oncoethix Sa | Formulation pharmaceutique contenant des composés thienotriazolodiazepine |
Cited By (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10676484B2 (en) | 2010-05-14 | 2020-06-09 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating leukemia |
US10407441B2 (en) | 2010-05-14 | 2019-09-10 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating neoplasia, inflammatory disease and other disorders |
US10751342B2 (en) | 2010-06-03 | 2020-08-25 | Pharmacyclics Llc | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
US10653696B2 (en) | 2010-06-03 | 2020-05-19 | Pharmacyclics Llc | Use of inhibitors of bruton's tyrosine kinase (BTK) |
US10004745B2 (en) | 2010-06-03 | 2018-06-26 | Pharmacyclics Llc | Use of inhibitors of Bruton'S tyrosine kinase (Btk) |
US11672803B2 (en) | 2010-06-03 | 2023-06-13 | Pharmacyclics Llc | Use of inhibitors of Brutons tyrosine kinase (Btk) |
US10004746B2 (en) | 2010-06-03 | 2018-06-26 | Pharmacyclics Llc | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
US10016435B2 (en) | 2010-06-03 | 2018-07-10 | Pharmacyclics Llc | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
US10478439B2 (en) | 2010-06-03 | 2019-11-19 | Pharmacyclics Llc | Use of inhibitors of bruton's tyrosine kinase (Btk) |
US9814721B2 (en) | 2010-06-03 | 2017-11-14 | Pharmacyclics Llc | Use of inhibitors of bruton'S tyrosine kinase (BTK) |
US9758524B2 (en) | 2011-07-19 | 2017-09-12 | Merck Sharp & Dohme B.V. | 4-imidazopyridazin-1-yl-benzamides as Btk inhibitors |
US9290504B2 (en) | 2011-07-19 | 2016-03-22 | Merck Sharp & Dohme B.V. | 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as Btk inhibitors |
US10239883B2 (en) | 2011-07-19 | 2019-03-26 | Merck Sharp & Dohme B.V. | 4-imidazopyridazin-1-yl-benzamides as BTK inhibitors |
US9790226B2 (en) | 2011-07-19 | 2017-10-17 | Merck Sharp & Dohme B.V. | 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as BtK inhibitors |
US10934296B2 (en) | 2011-07-19 | 2021-03-02 | Merck Sharp & Dohme B.V. | 4-imidazopyridazin-1-yl-benzamides as Btk inhibitors |
US9718828B2 (en) | 2011-07-19 | 2017-08-01 | Merck Sharp & Dohme Corp. | BTK Inhibitors |
US10954567B2 (en) | 2012-07-24 | 2021-03-23 | Pharmacyclics Llc | Mutations associated with resistance to inhibitors of Bruton's Tyrosine Kinase (BTK) |
US11446309B2 (en) | 2013-11-08 | 2022-09-20 | Dana-Farber Cancer Institute, Inc. | Combination therapy for cancer using bromodomain and extra-terminal (BET) protein inhibitors |
US10328080B2 (en) | 2013-12-05 | 2019-06-25 | Acerta Pharma, B.V. | Therapeutic combination of PI3K inhibitor and a BTK inhibitor |
US10925881B2 (en) | 2014-02-28 | 2021-02-23 | Tensha Therapeutics, Inc. | Treatment of conditions associated with hyperinsulinaemia |
US9885086B2 (en) | 2014-03-20 | 2018-02-06 | Pharmacyclics Llc | Phospholipase C gamma 2 and resistance associated mutations |
US9937171B2 (en) | 2014-04-11 | 2018-04-10 | Acerta Pharma B.V. | Methods of blocking the CXCR-4/SDF-1 signaling pathway with inhibitors of bruton's tyrosine kinase |
US11084793B2 (en) | 2014-05-01 | 2021-08-10 | Celgene Quanticel Research, Inc. | Inhibitors of lysine specific demethylase-1 |
EP3137086A4 (fr) * | 2014-05-02 | 2017-12-27 | Oncoethix GmbH | Methode de traitement de lymphome non hodgkinien resistant, de medulloblastome et/ou de cancer bronchopulmonaire non a petites cellules alk+ a l'aide de composes de thienotriazolodiazepine |
US9949971B2 (en) | 2014-06-17 | 2018-04-24 | Acerta Pharma B.V. | Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor and/or a JAK-2 inhibitor |
US11654143B2 (en) | 2014-08-11 | 2023-05-23 | Acerta Pharma B.V. | Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, a JAK-2 inhibitor, and/or a BCL-2 inhibitor |
US11166951B2 (en) | 2014-08-11 | 2021-11-09 | Acerta Pharma B.V. | Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, a JAK-2 inhibitor, and/or a BCL-2 inhibitor |
US10124009B2 (en) | 2014-10-27 | 2018-11-13 | Tensha Therapeutics, Inc. | Bromodomain inhibitors |
CN108033961A (zh) * | 2015-04-15 | 2018-05-15 | 上海方楠生物科技有限公司 | 一种艾德力布的无定型物及其制备方法 |
CN106146352A (zh) * | 2015-04-16 | 2016-11-23 | 上海医药工业研究院 | Idelalisib中间体及其制备方法 |
WO2016176335A1 (fr) | 2015-04-27 | 2016-11-03 | Concert Pharmaceuticals, Inc. | Otx-015 deutéré |
US11059829B2 (en) | 2015-07-02 | 2021-07-13 | Acerta Pharma B.V. | Crystal forms of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide maleate |
US11820777B2 (en) | 2015-07-02 | 2023-11-21 | Acerta Pharma B.V. | Crystal forms of (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide |
US10167291B2 (en) | 2015-07-02 | 2019-01-01 | Acerta Pharma B.V. | Pharmaceutical composition comprising a crystal form of (S)-4-(8-amino-3-(1-(but-2-ynoyl) pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide |
US11666580B2 (en) | 2015-08-10 | 2023-06-06 | Dana-Farber Cancer Institute, Inc. | Mechanism of resistance to bet bromodomain inhibitors |
WO2017059319A3 (fr) * | 2015-10-02 | 2017-10-12 | Dana-Farber Cancer Institute, Inc. | Polythérapie par inhibiteurs de bromodomaine et blocage de point de contrôle |
JP2018530554A (ja) * | 2015-10-02 | 2018-10-18 | ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド | ブロモドメイン阻害薬及びチェックポイント阻害薬による併用療法 |
WO2017112703A1 (fr) * | 2015-12-24 | 2017-06-29 | Celgene Quanticel Research, Inc. | Thérapie d'association par inhibiteur de bromodomaine et de protéine extra-terminale |
WO2018013693A1 (fr) * | 2016-07-13 | 2018-01-18 | Celgene Corporation | Dispersions solides et co-cristaux comprenant des compositions de 3-(4-amino-1-oxo-1,3-dihydro-iso-indol-2-yl)-pipéridine-2,6-dione et procédés pour les utiliser |
US10881655B2 (en) | 2016-10-27 | 2021-01-05 | Celgene Quanticel Research, Inc. | Bromodomain and extra-terminal protein inhibitor combination therapy |
US10166227B2 (en) | 2016-10-27 | 2019-01-01 | Celgene Quanticel Research, Inc. | Bromodomain and extra-terminal protein inhibitor combination therapy |
US11464771B2 (en) | 2016-10-27 | 2022-10-11 | Celgene Quanticel Research, Inc. | Bromodomain and extra-terminal protein inhibitor combination therapy |
WO2018081475A1 (fr) * | 2016-10-27 | 2018-05-03 | Celgene Quanticel Research, Inc. | Polythérapie par inhibiteur de protéine à bromodomaine et domaine extra-terminal |
US10576075B2 (en) | 2016-10-27 | 2020-03-03 | Celgene Quanticel Research, Inc. | Bromodomain and extra-terminal protein inhibitor combination therapy |
CN107033147A (zh) * | 2017-04-25 | 2017-08-11 | 东南大学 | 一种bet/hdac双靶点抑制剂及其制备方法和应用 |
WO2019020606A1 (fr) * | 2017-07-26 | 2019-01-31 | F. Hoffmann-La Roche Ag | Polythérapie avec un inhibiteur bet, un inhibiteur bcl-2 et un anticorps anti-cd20 |
CN110869391A (zh) * | 2017-07-26 | 2020-03-06 | 豪夫迈·罗氏有限公司 | 用BET抑制剂,Bcl-2抑制剂和抗CD20抗体的组合疗法 |
US10906917B2 (en) | 2018-06-13 | 2021-02-02 | Dybly Ag | Preparation of condensed triazepine derivatives and their use as BET inhibitors |
US11708374B2 (en) | 2018-06-13 | 2023-07-25 | Worg Pharmaceuticals (Zhejiang) Co., Ltd. | Preparation of condensed triazepine derivatives and their use as BET inhibitors |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2015018522A1 (fr) | Inhibiteur de bromodomaine bet présentant une synergie avec plusieurs agents anti-cancéreux dans des modèles cliniques de lymphome diffus de cellule b de grande taille (dlbcl) | |
AU2013340483B2 (en) | Pharmaceutical formulation containing thienotriazolodiazepine compounds | |
EP3030242A1 (fr) | Procédé de traitement de lymphome diffus à grande cellules b (ldgcb) au moyen d'un inhibiteur de bromodomaine de bet | |
AU2015252940A1 (en) | Method of treating resistant non-Hodgkin lymphoma, medulloblastoma, and/or ALK+non-small cell lung cancer using thienotriazolodiazepine compounds | |
US9956228B2 (en) | Method of treating acute myeloid leukemia and/or acute lymphoblastic leukemia using thienotriazolodiazepine compounds | |
WO2015169953A1 (fr) | Méthode de traitement d'un gliome à l'aide de composés thiénotriazolodiazépine | |
WO2015169951A1 (fr) | Méthode de traitement du cancer du sein triple négatif à l'aide de composés de thiénotriazolodiazépine | |
EP3074018A1 (fr) | Méthode de traitement de la leucémie au moyen d'une formulation pharmaceutique contenant des composés de thiénotriazolodiazépine | |
US20170281642A1 (en) | Methods of treating acute myeloid leukemia or acute lymphoid leukemia using pharmaceutical compositions containing thienotriazolodiazepine compounds | |
WO2015018520A1 (fr) | Inhibiteur bet-brd représentant un nouvel agent pour un lymphome anaplasique à grandes cellules alk positif | |
US9795612B2 (en) | Pharmaceutical formulation containing thienotriazolodiazepine compounds | |
AU2015273032A1 (en) | Method of treating non-small cell lung cancer and/or small cell lung cancer using thienotriazolodiazepine compounds | |
US9820992B2 (en) | Method of treating non-small-cell lung cancer using pharmaceutical formulation containing thienotriazolodiazepine compounds | |
WO2015018523A1 (fr) | Nouvel inhibiteur de bet-brd pour le traitement de tumeurs solides | |
WO2015168587A1 (fr) | Procédé de traitement de myélome multiple résistant et de lymphome des cellules du manteau à l'aide de composés de thiénotriazolodiazépine | |
WO2016026912A1 (fr) | Méthode de traitement de lymphomes à l'aide de composés thiénotriazolodiazépine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14755589 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 14755589 Country of ref document: EP Kind code of ref document: A1 |